Frontline Irinotecan Liposome OKed in Mets Pancreatic Cancer

The approval was based on improved overall and PFS with irinotecan liposome alongside oxaliplatin, fluorouracil, and leucovorin vs gemcitabine plus nab-paclitaxel.

Related Keywords

Julie Fleshman , National Comprehensive Cancer Network , Pancreatic Cancer Action Network , Drug Administration , Ipsen Biopharmaceuticals Inc , Ipsen Biopharmaceuticals , Malignant Pancreatic Neoplasm , Pancreatic Cancer , Ancer Of The Pancreas , Cancer , Alignant Neoplasia , Arcinoma , Alignant Neoplasm , Pancreatic Adenocarcinoma , Denocarcinoma Of The Pancreas , Adenocarcinoma , Diarrhea Diarrhoea , Abdominal Pain , Pain Management , Prabdominal , Alabama , Chemotherapy , Fatigue , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Hemoglobin , Tb ,